Paul joined NEA in 2008. He focuses on later-stage life sciences investments. Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Paul received a BS in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst (CFA) designation. He is a Director of Allakos (NASDAQ: ALLK), TRACON Pharmaceuticals (NASDAQ: TCON), and Trillium Therapeutics (NASDASQ: TRIL); he was previously a Director of TESARO (NASDAQ: TSRO) and manages a number of NEA’s public healthcare investments.
News
- October 3, 2018
Companies
- All
- Featured
- Current
- Boards
- IPOs
- Acquisitions
- Acadia Pharmaceuticals
- Addex Therapeutics
- Affimed N.V.
- Akari Therapeutics
- Allakos
- Aurinia Pharmaceuticals
- AVEO Oncology
- Cascadian Therapeutics
- Champions Oncology
- CTI Biopharma
- Erytech Pharma SA
- Geron
- Immunomedics
- Infinity Pharmaceuticals
- Interleukin Genetics
- InterMune
- Inventiva Pharma
- Lexicon Pharmaceuticals
- MEI Pharma
- Nektar Therapeutics
- Orexigen Therapeutics
- Regulus Therapeutics
- Repros Therapeutics
- Rigel Pharmaceuticals
- Savara
- Seattle Genetics
- SuperGen
- Tesaro
- TRACON Pharmaceuticals
- Trillium Therapeutics
- Verona Pharma
- Viracta Therapeutics (formerly Sunesis)
- VistaGen Therapeutics
- Xenon Pharma